ALIGNANT gliomas and astrocytomas account for approximately 50% of primary CNS tumors in adults: glioblastomas multiforme account for approximately 30%, AAs for approximately 10%, and lowgrade astrocytomas for approximately 10%. It has been reported that the median survival period of patients with AA is 10 to 40 months (~ 20-30 months on average). 6, 16, 20, 22 It has been reported as well that the major prognostic factors for patients with AA are age, KPS status, and extent of surgery. In some studies investigators have also shown that the presence of ringed contrast enhancement, score on the Ki 67 labeling index, total radiation dose, the presence of convulsion, microvascular density, and expression of vascular endothelial growth factor are prognostic factors. 1, 2, 5, 6, 8, 16, 20, 22 Despite the availability of combined multimodality treatment, AA has an unfavorable prognosis. Surgery and radiation therapy are essential for radical treatment of malignant astrocytoma, but an optimal treatment regimen has not yet been established. The purpose of this study was to evaluate the outcome of treatment in 170 patients with AA and to estimate the prognostic factors and contribution of each parameter of treatment by using multivariate analysis.
which the histopathological diagnosis was Grade III astrocytoma (Grade III oligoastrocytoma or other Grade III gliomas were excluded). The histopathological diagnosis was determined based on the findings of at least one pathologist and one neurosurgeon. Histopathological grading was determined on the basis of the latest World Health Organization classification. The final follow-up date was May 23, 2003 . Astrocytomas that were initially treated as Grade III lesions and changed to Grade IV during the course of follow up were included in this study. Astrocytomas that were not Grade III at the time of initial treatment were excluded.
The KPS status was determined according to the criteria of the Eastern Cooperative Oncology Group before treatment. 12 This was accomplished using enhanced CT scans and/or T 2 -weighted or enhanced T 1 -weighted MR images. Preoperative and postoperative MR imaging was routinely performed after 1987. The size of the tumor was measured as accurately as possible by more than one radiologist and neurosurgeon. Because of the difficulty in measuring tumor volume in cases treated early in the study, the methods for assessing the size of the tumor were unified into measurement of its long axis.
Surgery and Chemotherapy
The extent of surgery was evaluated on postoperative MR images and/or CT scans obtained within 72 hours postsurgery. Comparing these with preoperative MR and/or CT images, gross-total resection of the tumor was defined as resection with no macroscopic residual tumor, subtotal resection was defined as more than 75% resection, and partial resection was defined as less than 75% resection. Biopsy (including open procedures and needle biopsy) that was performed only for the purpose of histological diagnosis was defined as less than 10% resection. Although there was uncertainty in evaluating the extent of surgery before the advent of MR imaging, this factor was assessed based on CT findings and the surgeon's judgment as far as possible. Surgery (or biopsy) was performed before radiation therapy and chemotherapy in almost all cases. Chemotherapy was routinely combined as much as possible. Patients who had renal dysfunction, hepatic dysfunction, or poor KPS status or who did not give consent for chemotherapy did not receive it. Nimustine hydrochloride (2-3 mg/kg weekly) was mainly used in adjuvant chemotherapy.
Radiation Therapy
All patients were treated with 4-to 10-MV photons (almost all of them with 10-MV photons) by using a linear accelerator, and all were immobilized in a resinous shell during the treatment. The standard dose of WBRT was 30 Gy in 15 fractions (plus local boost irradiation of 30 Gy in 15 fractions). The WBRT field included the cerebrum, cerebellum, and brainstem (above the posterior cranial fossa), and parallel-opposed lateral fields were used. The extended local irradiation field included the whole T 2 -weighted high-intensity region visualized on MR images or a 2-to 3-cm margin around the tumor, and usually more than two fields were used. The fractionation regimen was as follows: 1) conventional fractionation (2 Gy/day with a total of 10 Gy delivered in five fractions within 1 week); 2) uneven fractionation (a combination of high-dose and low-dose fractions [4-5 Gy on Day 1 and 1-1.5 Gy/day between Days 2-5] with a total of 7-9 Gy delivered in three-five fractions/week); and 3) hyperfractionation (1.2 Gy/fraction, two fractions/day for a total of 12 Gy delivered in 10 fractions within 1 week). The conventional fractionation regimen was mainly used from 1981 through 1985, the uneven fractionation regimen from 1986 through 1995, and the hyperfractionation regimen from 1995 through 2003. A single dose of 15 Gy delivered using 8-to 10-MeV electrons was used for IORT.
Treatment-Related Toxicity
Toxicity was clinically diagnosed on the basis of common toxicity criteria (version 2.0). Patients in whom radiographically confirmed changes without recurrence were demonstrated (such as Ն Grade 3 leukoencephalopathyassociated radiological findings, or brain necrosis that was diagnosed on the basis of changes seen on follow-up CT or MR images, clinical examination, and/or histopathological findings) were classified as suffering treatment-related toxicity.
Statistical Analysis
Survival time was calculated from the date of first treatment to the date of death. Progression-free survival was calculated from the date of first treatment to the date of first progression (local recurrence or distant metastasis). Survival curves were analyzed using the Kaplan-Meier method and the log-rank test. The Cox proportional hazards model Table 2 ). Analyses of prognostic factors were performed for all patients whose tumor diagnosis was Grade III glioma. Statistical relationships between significant prognostic factors were analyzed using the chi-square test.
Results

Data from patients with AA treated between May 1981
and March 2002 at our institution were analyzed. At least two cases of Grade III astrocytoma (1.1%) were histologically proven to be Grade IV astrocytoma at the time of recurrence. One hundred sixty-one patients completed the course of treatment, but nine did not because of deterioration of their general condition due to uncontrolled tumor growth. At the final follow-up date, 110 patients (64.7%) were dead and 60 (35.3%) were alive. Of the patients who had died, 102 (92.7%) died of primary disease and eight (7.3%) died of intercurrent disease.
Survival analysis of the 170 patients showed that the MST was 33.6 months and that the 2-and 5-year survival rates were 57.1 and 33.8%, respectively ( Fig. 1) . Two-year and 5-year progression-free survival rates were 49.3 and 30.2%, respectively. Table 3 shows the results of univariate and multivariate analyses of prognostic factors for the 170 patients. In the multivariate analysis, site of the lesion (p = 0.002), extent of surgery (p = 0.001), KPS status (p = 0.021), age (p = 0.024), and total dose of radiation therapy (p = 0.029) were significant prognostic factors. Patient sex, tumor size, treatment with or without chemotherapy, treatment with or without IORT, period of EBRT, irradiation field, fractionation regimen of radiation therapy, and period of treatment were not statistically significant in multivariate analysis.
The patients in whom primary lesions were located in the frontal or parietal lobe had a significantly more favorable prognosis than did the patients who had primary lesions in other sites (MST 48.9 months compared with 22.6 months [p Ͻ 0.0001, log-rank test]). The patients who had a good KPS score before treatment had a significantly more favorable prognosis than did those in whom a poor KPS score was noted (MST 41 months compared with 10 months [p Ͻ 0.0001, log-rank test]). The patients who were 50 years of age or younger had a significantly more favorable prognosis than did the patients who were older than 50 years of age (MST 44.9 months compared with 19.0 months [p Ͻ 0.0001, log-rank test]). Figure 2 shows survival curves according to extent of surgery. The patients who underwent total or subtotal resection of the tumor showed a significantly more favorable prognosis than did those who underwent partial resection or biopsy only (5-year survival rate 54.0% compared with 17.5%; MST 62.6 months compared with 22.9 months [p Ͻ 0.0001, log-rank test]; HR 0.67; 95% CI 0.52-0.85 [p = 0.001]). In the survival analysis based on fine distinctions, the MSTs of patients in the total resection, subtotal resection, partial resection, and biopsy-only groups were 86.4, 61.6, 22.9, and 23.4 months, respectively (p Ͻ 0.0001, log-rank test [data not shown]). The prognosis of patients in the total resection group was the most favorable, and significantly so, whereas the prognosis of those in the subtotal resection group was slightly worse, although the difference was not significant (p = 0.55, log-rank test). Nevertheless, the prognosis of the patients in the subtotal resection group was significantly more favorable than for those in the partial resection and biopsy-only groups (p = 0.007, log-rank test). Figure 3 shows survival curves according to the total dose of radiation therapy. The group treated with a high dose (Ͼ 60 Gy, 91 patients) showed a significantly more favorable prognosis than did the one treated with a low dose (Յ 60 Gy, 79 patients) (5-year survival rate in the high-dose group was 45.0% compared with 21.1% in the low-dose group; MST was 48.9 months compared with 21.6 months ([p = 0.0006, log-rank test]; HR 0.96; 95% CI 0.93-0.99 [p = 0.029]). Figure 4 shows survival curves according to extent of surgery (Ն subtotal resection or Յ partial resection) and total radiation dose (Ͼ 60 Gy or Յ 60 Gy). Patients were divided into three categories (Group A, those who underwent Ն subtotal resection and received a Ͼ 60-Gy radiation dose; Group B, those who underwent Յ partial resection and received a Ͼ 60-Gy radiation dose, or Ն subtotal resection and Յ 60 Gy; and Group C, those who underwent Յ partial resection and received a Յ 60-Gy radiation dose). Figure 5 shows survival curves according to total radiation dose in the 56 patients who underwent gross-total resection of tumor. The patients treated with a high dose (Ͼ 60 Gy, 33 patients) showed a significantly more favorable prognosis than the ones treated with a low dose (Յ 60 Gy, 23 patients). The 5-year survival rate in the high-dose group was 65.6%, compared with 38.3% in the low-dose group ([p = 0.04, log-rank test]; HR 0.67; 95% CI 0.44-1.00 [p = 0.05]).
Treatment-associated brain necrosis was seen in 10 (5.9%) of the 170 patients ( Table 4 ). The median period before brain necrosis occurred was 28.3 months (range 8.2-76.2 months). The mean total radiation dose for patients with brain necrosis was 70.6 Ϯ 12.9 Gy, and that for patients without brain necrosis was 62.5 Ϯ 10.7 Gy (mean Ϯ standard deviation, p = 0.02). The total radiation dose was significantly higher in patients in whom brain necrosis was noted. In the group of patients who underwent chemotherapy, five (4%) of 117 had brain necrosis, and in the group of patients who underwent IORT, three (11%) of 28 had brain necrosis. No significant relationships were found between brain necrosis, use of IORT, and use of chemotherapy. Four of the 10 patients with brain necrosis died; however, as shown in the table, no patient died of radiationinduced brain necrosis. Most of the patients with brain necrosis showed few neurological symptoms. 
Discussion
Significant prognostic factors for patients with AA in multivariate analysis were as follows: site of the lesion, extent of surgery, KPS status, patient's age, and total dose of radiation therapy. According to these results, factors on the patient's side, such as site, KPS, and age, account for the majority of prognostic factors. As shown in previous studies, these factors have a great impact on the prognosis of patients with high-grade glioma. 2, 6, 8, 11, 16, 20, 22 Extent of surgery was the most powerful prognostic factor in the treatment parameters, and total dose of radiation therapy was the second most important prognostic factor. Several authors have reported that extent of surgery has a strong correlation with the prognosis of patients, and the results of our study are compatible with those of the other studies.
11, 16 Curran et al. 3 suggested that resection did not have a great impact on prognosis in patients with glioblastoma multiforme located in the supratentorial area compared with the impact of radiation alone. However, in this study of AAs located in the supratentorial area (132 tumors), the prognosis of patients who underwent total or subtotal resection was significantly more favorable than that of patients who underwent partial resection or biopsy only (MST 86.4 compared with 24.7 months, p Ͻ 0.0001). Although there are various opinions about the significance of surgery, 1, 6, 20 the results of the aforementioned study imply that surgery is an essential modality and that the extent of resection has a great impact on prognosis in patients with AA.
It is known that malignant glioma is a radioresistant tumor both in vitro and in vivo, and it is difficult to control the lesion by using irradiation alone. 14, 16, 19 The results of our study also support the suggestion that resection of as much of the tumor as possible is a precondition for a favorable prognosis. According to our results, total radiation dose was the second most significant prognostic factor in the parameters of treatment. This finding has no relation to the presence of postoperative residual tumor: patients in the higher total dose group, even those who underwent total or subtotal resection, showed a significantly more favorable prognosis (80 patients, 5-year survival rates 63.1% compared with 31.7% [p = 0.003, log-rank test; data not shown]). Also, as shown in Fig. 5, a radiation than 60 Gy significantly contributes to improvement in the patients' prognosis, even in cases in which gross-total resection of the tumor was successfully performed. This result supports the suggestion that postoperative radiation therapy at an insufficient dose leads to local recurrence, even if the primary lesion has been totally resected, and that combined radiation therapy is essential for treatment of AA. Malignant glioma often spreads microscopically beyond the macroscopic margin visualized on MR or CT images. 7, 9 It is therefore thought to be difficult to resect microscopic malignant cells invading peripheral tissue around the tumor. On the other hand, malignant glioma is radioresistant, 14, 16 and it is therefore difficult to eliminate macroscopic tumor by using radiotherapy alone. It seems that the role of surgery is removal of the bulk of the tumor, and that the role of radiation therapy is elimination of residual microscopic malignant cells. Surgery and radiation therapy have distinct roles, and both modalities seem to be essential for the treatment of Grade III glioma. Results of survival analysis taking into account the combination of these modalities seem to support this opinion (Fig. 4) .
Miller et al. 8 reported that total radiation dose was one of the significant prognostic factors. The results of our study are consistent with their results in that total radiation dose had an impact on the prognosis of patients with malignant glioma. However, these authors reported that no additional benefit could be obtained for doses greater than 60 Gy, whereas the results of our study are quite different in this point. This difference may be due to the number of patients in the Miller study (16 with AA and 66 with glioblastoma multiforme) who received radiation therapy at that time. In the present study, which includes a much larger cohort (170 patients with only AAs), we suggest that postoperative radiation therapy at a dose of more than 60 Gy is required for local control, and this speculation seems to be valid from the viewpoint of biological and clinical radiosensitivity of malignant glioma cells. 14, 19 Use of chemotherapy was not a significant prognostic factor in this study, either in univariate or multivariate analysis, and its use was not significantly related to brain necrosis. The role of chemotherapy in high-grade glioma is controversial. Nevertheless, several investigators have reported a small but significant benefit for survival in patients with high-grade glioma. 4, 21 Although the impact of chemotherapy is not superior to that of surgery and radiotherapy, further investigation of optimal timing, dose intensity, and the optimal drug combination is required. Use of IORT was also not a significant prognostic factor in multivariate analysis, and the significance of IORT for treatment of highgrade glioma is controversial. Several investigators have suggested that there is no significant benefit of IORT, 10 whereas others have suggested that IORT is effective for patients with high-grade glioma, but the survival benefit has not been clarified. 13, 15 The prognostic significance of IORT in patients with Grade III astrocytoma was not shown in this study.
One of the problems is occurrence of toxicity, such as brain necrosis. Five of the 10 patients with brain necrosis in our study underwent uneven fractionation of radiotherapy. Brain necrosis occurred in those five despite relatively low doses of total radiation without IORT. A large single-fraction size (4-5 Gy/fraction) was used in this regimen. It is known that irradiation with a large single-fraction size is one of the risk factors of late toxicity, especially in the CNS. 23 Care should be taken when using a large singlefraction size for treatment of CNS tumors. Hyperfractionated radiation therapy uses a small single-fraction size (1.2 Gy/fraction); nevertheless, the standard dose is relatively high. Therefore, the use of IORT should be determined with caution. In our study, the significance of the fractionation regimen of radiotherapy combined with the use of IORT has not been shown in the multivariate analysis of patient survival. However, a large fraction size for EBRT or IORT seemed to be one of the causes of late toxicity.
The difference in influence of fraction size between malignant glioma and healthy CNS tissue may come from the difference between alpha/beta values in malignant tissue and those in healthy tissue from the viewpoint of radiation biology. It is reported that the alpha/beta value of malignant glioma is high (usually Ն 10 Gy), whereas the alpha/beta value of healthy CNS tissue is low (usually Ͻ 5 Gy). 17, 18, 24 This difference between alpha/beta values in tumor and healthy tissue means that healthy CNS tissue is more sensitive to an increase in the fraction size of irradiation. Based on these results, it seems that to avoid late toxicity a large fraction size of EBRT or IORT should not be routinely used for treatment of CNS tumors. However, as shown in Table  4 , there was no treatment-related death in patients in our study. It is therefore thought that irradiation of more than 60 Gy will not lead to dangerous and intolerable toxicity. As shown by survival curves in Fig. 3 , the survival benefit of irradiation with more than 60 Gy seems to exceed the risk of radiation-induced toxicity.
Conclusions
The results of this retrospective study showed significantly better survival in patients who underwent surgery and radiation therapy for treatment of AA. As complete a tumor resection as possible and combining surgery with high-dose irradiation seem to improve the prognosis of patients with these lesions. The MST of patients with AA has been extended by approximately one and a half times in recent decades, but the optimum dose, field of radiation therapy, fractionation regimen, and regimen of chemotherapy have not yet been established. Further investigation of treatment parameters is required for improvement of treatment protocols for AA.
